Replies to post #113540 on Biotech Values

[ghmm]

There seems to be a lot of big pharma interest in PARP. I am not that familiar with them and only recently started paying some attention to the area because of the deal BMRN did (though it wouldn't have been my first or even second choice of candidate for them :-)). Any one have thoughts/opinions on the target in general?

Six highly potent and specific PARP inhibitors are
currently in clinical development in oncology [7]. BSI
201 (BiPar Sciences Inc., South San Francisco, CA, USA)
has entered a phase III trial for triple-negative breast cancer
in combination with gemcitabine and carboplatin (G/C).
Three agents – olaparib (AZD 2281; AstraZeneca, London,
UK), ABT888 (Abbott Laboratories, Abbott Park, IL, USA),
and AG014966 (Pfizer Inc., New York, NY, USA) – are
in phase II clinical trials as single agents or in combination
with chemotherapy. Two PARP inhibitors are in phase I
trials: MK4827 (Merck, Darmstadt, Germany) and CEP9722 (Cephalon, Inc., Frazer, PA, USA). Two additional
agents entered clinical development but have not
been pursued: GPI 21016 (Sanofi-Aventis, Paris, France)
and INO-1001 (Genentech, Inc., South San Francisco,
CA, USA).